Innovative phase 2 trial targets advanced liver cancer
UCL study will assess safety and efficacy of MTL-CEBPA in combination with standard of care second-line sorafenib versus using sorafenib alone
The first patient received a dose as part of a clinical trial evaluating the use of a new treatment for an advanced type of liver cancer. MTL-EBPA with sorafenib is being tested for the treatment of advanced hepatocellular carcinoma (HCC).
HCC is the most common type of primary liver cancer in adults and the third leading cause of cancer-related death worldwide. It is also the most common cause of death in people with end-stage liver disease.
The global Phase 2 OUTREACH-2 clinical trial will evaluate the safety and efficacy of MTL-CEBPA in combination with standard second-line care sorafenib, compared to sorafenib alone. Up to 150 patients will participate in the trial.
“Advanced liver cancer remains a significant unmet medical need, particularly for patients who are resistant to routine first-line treatment,” commented Professor Tim Meyer, Professor of Experimental Cancer Medicine at University College London and chief researcher of the study.
“This combination treatment demonstrated intriguing activity signals in a phase 1b trial, including durable and complete tumor responses. We believe that the immunological activity of MTL-CEBPA in the tumor microenvironment allows for greater efficacy of sorafenib and we are excited to seek to validate these early results in this Phase 2 clinical trial,” he added.
As the very first RNA therapy to enter the clinic, MTL-EBPA is being studied as a combination cancer therapy. It works by reducing or suppressing one of the main defense mechanisms that tumors use to resist attacks from the immune system. This ensures that the tumor can be attacked by tumor-targeting drugs as well as the immune system.
An RNA therapy is designed to correct the RNA mutation of a person with a genetic disease. By doing so, RNA can be used to create the missing proteins a cell needs and eliminate the underlying causes of disease.